T. E. Areyan

T. E. Areyan

Auto-generated profile, based on publicly available information

T. E. Areyan

Sechenov First Moscow State Medical University (Sechenov University)

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2025 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
MOMaria Osminina
Maria Osminina
NPNadezhda Podchernyaeva
Nadezhda Podchernyaeva
LKL.G. Khachatryan
L.G. Khachatryan
OLOksana Lazareva-Batyreva
Oksana Lazareva-Batyreva
SOShpitonkova Olga
Shpitonkova Olga
TAT.E. Areian
T.E. Areian
A retrospective study contains clinical and immunological characteristics of juvenile systemic scleroderma manifestations in 78 children according to data from a single rheumatology center. The average age of onset was 8.3 years, girls outnumbered boys, the form with diffuse skin involvement was more common, and among visceral involvement, the gastrointestinal tract and lungs were the most commonly affected; antinuclear factor was detected in 81% of children, anticentromere antibodies in 31%, and antitopoisomerase antibodies in 8.5%. The 5-year survival rate of patients in the main group was 100%, and the probability of survival at 74 months was 70%. Our data largely coincide with the studies of other authors. No obvious natural pathomorphosis of juvenile systemic scleroderma has been established in the 2000s compared to 1960–1980; therapeutic pathomorphosis of the disease is likely to occur. Key words: pathomorphosis, age of onset, visceral involvement, autoantibodies, survival

25 September 2023 in Pediatric dentistry and dental prophylaxis
Verified
Journal Article
Open access
PDF file
DVD. E. Vadiyan
D. E. Vadiyan
OAOleg Admakin
Oleg Admakin
LKL. G. Khachatryan
L. G. Khachatryan
TKT. S. Kaminskaya
T. S. Kaminskaya
NMNatalia Morozova
Natalia Morozova
TAT. E. Areyan
T. E. Areyan
Relevance. Children with autism spectrum disorder (ASD) frequently exhibit poorer oral hygiene and altered oral and gut microbiota, influenced by behavioral features, sensory hypersensitivity, and feeding difficulties. Evidence for non-invasive, home-based caries-prevention strategies in this population remains limited. The evaluation of the clinical efficacy of available preventive agents, including calcium-enriched oral foam and the oral probiotic Streptococcus salivarius K12, is considered a relevant topic of investigation in pediatric dentistry. Materials and methods. In this prospective controlled study, 122 children with ASD aged 3–9 years received 30-day preventive regimens including a calcium-enriched oral foam (Group 1) or S. salivarius K12 (Group 2). A control group comprised 54 neurotypical children. Oral health status was assessed using the Fedorov–Volodkina Hygiene Index; the presence and severity of black stain plaque (extrinsic discoloration) were recorded clinically; caries experience was quantified as the combined dmft + DMFT score. Oral and fecal microbiota were profiled by GC–MS. Results. At baseline, children with ASD had significantly poorer oral hygiene and higher caries prevalence than neurotypical controls. GC–MS profiling indicated pronounced dysbiosis in both oral and intestinal samples in the ASD cohort, with correlations across sites for pathogenic taxa ( e.g., Streptococcus mutans, Staphylococcus aureus, Helicobacter pylori ). A statistically significant decrease in oral hygiene index scores was observed in both younger and older age groups following the use of calcium-enriched oral foam and the Streptococcus salivarius K12 probiotic. After 30 days of preventive use, the proportion of children with elevated levels of S. mutans , S. aureus , and other pathogenic microorganisms decreased in oral and gut samples. No statistically significant between-regimen differences in improvement were observed across age groups. Both interventions demonstrated comparable efficacy. Conclusion. Calcium-enriched oral foam and S. salivarius K12, used as home-based adjuncts, improved plaque-related indices and favorably modulated microbiota profiles in children with ASD. These non-invasive measures may be recommended as part of comprehensive dental care for this population.

25 December 2025 in Эндодонтия Today
Verified
Journal Article
Closed access
DVD. E. Vadiyan
D. E. Vadiyan
OAOleg Admakin
Oleg Admakin
LKL. G. Khachatryan
L. G. Khachatryan
TKT. S. Kaminskaya
T. S. Kaminskaya
EKE. V. Kasanave
E. V. Kasanave
TAT. E. Areian
T. E. Areian
INTRODUCTION. Children with autism spectrum disorder (ASD) often exhibit altered oral sensory processing, atypical feeding patterns, and non-standard responses to dental stimuli, complicating endodontic care. AIM. To profile feeding behavior, mastication, and swallowing in ASD and to identify endodontically relevant risks: verification of odontogenic pain, effectiveness of local infiltration anesthesia, and tolerance to rubberdam isolation. MATERIALS AND METHODS. Observational controlled study of 178 children aged 3–9 years (ASD n = 124, controls n = 54). Caregiver questionnaires and clinician-rated protocols assessed meal frequency/duration, oral sensory responses, mastication, and swallowing. Dental visits were evaluated for pain verification, infiltration-anesthesia performance, and isolation tolerance. Between-group differences were tested at α = 0.005, significant effects were observed for all p ≤ 0.003. RESULTS. ASD was associated with more frequent but smaller meals, prolonged mealtimes, heightened oral sensory reactivity, and higher rates of mastication/swallowing difficulties. In the dental setting, ASD patients more often demonstrated hard-to-verify odontogenic pain, variable infiltration-anesthesia efficacy, and poor tolerance to rubber-dam isolation. CONCLUSIONS. The ASD feeding / sensory profile differs from neurotypical peers and predicts challenges in pain verification and treatment tolerance. Routine pre-visit preparation and sensory-aware communication improve cooperation. Stepwise behavior guidance and flexible isolation strategies reduce aversive responses. When infiltration shows inconsistent effect, clinicians should reassess pain source, adapt anesthetic technique, and allow sufficient latency/graded dosing within safety limits. Integrating caregiver-reported feeding / sensory cues into chairside decisions increases anesthesia success and overall endodontic feasibility.

30 December 2025 in Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics)
Verified
Journal Article
Open access
PDF file
TKT. S. Kaminskaya
T. S. Kaminskaya
AKA. I. Krapivkin
A. I. Krapivkin
GVGrigory Vasilyev
Grigory Vasilyev
ADA. A. Dokshukina
A. A. Dokshukina
NPN. P. Prokopyeva
N. P. Prokopyeva
EBE. B. Batomunkueva
E. B. Batomunkueva
We describe a clinical case of leukencephalopathy, developmental delay, and episodic neurologic regression (LEUDEN, OMIM 618877) associated with variants in the EIF2AK2 gene, with an emphasis on clinico-pathogenetic links and potential therapeutic targets. A 2-year-old boy presented with psychomotor delay, spastic tetraparesis, and fever-induced episodes of regression; brain MRI showed hypomyelination and white-matter atrophy. Whole-exome sequencing identified a de novo pathogenic EIF2AK2 variant, c.325G>T (p.Ala109Ser, NM_001135651.3). The synthesis of clinical, neuroimaging, and genetic data is consistent with chronic hyperactivation of the integrated stress response (ISR) via the PKR–eIF2α pathway, leading to sustained eIF2α phosphorylation, impaired synthesis of myelin proteins, activation of apoptosis, and synaptic dysfunction; external stressors (infections) act as triggers of transient deterioration manifesting as regression of skills. The phenotype may mimic cerebral palsy with episodes of regression, underscoring the need for early molecular genetic confirmation in pediatric hypomyelination. The pathogenetic involvement of the ISR highlights the promise of targeted modulation of this pathway (e.g., ISR inhibitors), although the clinical efficacy of such strategies in LEUDEN requires further evaluation in controlled studies; early diagnosis and patient stratification are key to developing personalized treatment approaches.

1 January 2024 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
LKL.G. Khachatryan
L.G. Khachatryan
NGNatalia Geppe
Natalia Geppe
NGNatalia Golovanova
Natalia Golovanova
TKT.S. Kaminskaya
T.S. Kaminskaya
MCMoscow V.F.VOyno-Yasenetsky Scientific And Practical Center Of Specialized Medical Care For Children
Moscow V.F.VOyno-Yasenetsky Scientific And Practical Center Of Specialized Medical Care For Children
TAT.E. Areyan
T.E. Areyan
The article is devoted to one of the topical problems in paediatrics and child neurology - sleep disorders in children. This problem requires special attention due to its high incidence, clinical polymorphism and complexity of correction. Objective. To evaluate the efficacy of Homeostres preparation for the correction of sleep disorders in children. Patients and methods. A total of 112 patients aged 3 to 5 years 11 months (63% boys and 37% girls) were under observation. All children included in the study were distributed into 2 groups of 56 patients each using the method of simple randomisation. Group 1 patients received Homeostres 2 tablets 3 times a day without meals for 28 days. Patients of group 2 received gamma aminobutyric acid preparation in age-appropriate dose. All patients were observed 2 times: before the start of treatment (Visit 1) and on the 28th day (Visit 2) of the conducted therapy. The effectiveness of therapy was assessed taking into account the characteristics of emotional-behavioural sphere, characteristics of sleep/sleep quality using a special questionnaire, as well as the IMPSS parental assessment scale. Laboratory and instrumental studies included clinical blood analysis to exclude inflammatory process, transcranial dopplerography of cerebral vessels and 3-hour electroencephalographic monitoring of the brain. Results. All examined children initially had different degrees of sleep and sleep disorders within the framework of the diagnosis ‘insomnia’. The positive effect of Homeostres administration on all stages of sleep: initiation and consolidation, especially on the duration and nature of falling asleep, sleep phase and number of night awakenings was verified by statistical analysis. According to the data presented, the number of night awakenings decreased significantly during Homeostres administration: the number of children with 6 and more night awakenings decreased, the number of children with 5 night awakenings decreased by 1.5 times, the number of children falling asleep independently increased by 2 times (p < 0.008) and the number of children rocking to sleep decreased by 1.3 times. Parents reported decreased wakefulness and nighttime wakefulness and 67% of parents of children receiving Homeostres were satisfied with the outcome of the intervention. After 28 days of Homeostres, the duration of nocturnal sleep increased by an average of one hour and ranged from 7 to 12 hours M = 9 9 9 (SD = 1, CV = 13.2%, р = 0.001)), the average duration of nocturnal wakefulness decreased by a factor of 1.1 to 1.5 1.7 1.9 ± 0.5 hours (CV = 37.6%, р = 0.0001), and the duration of the sleep period decreased by a factor of 1.2 to an average of 32 34 36 min (SD = 6, CV = 18.1%). There was also a significant improvement of blood flow in the main great cerebral vessels and improvement of venous outflow in the vein of Galen, which can be partially explained by the presence of sympatho-regulating and vagolytic herbal components in Homeostres. Good tolerability of Homeostres in children and absence of adverse reactions were also noted. Comparative analysis with patients taking gamma aminobutyric acid showed no significant difference in the efficacy of the two drugs. Conclusion. The efficacy of the drug Homeostres for the correction of sleep disorders in children over 3 years of age has been demonstrated on representative material. The use of the drug improves sleep parameters, it has a good efficacy and safety profile, and can be recommended for widespread use in paediatric healthcare.